Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estradiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 0.83 |
| ▸ | LMNA | P02545 | 7/20 | 0.83 |
| ▸ | MAPT | P10636 | 5/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.83 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | PGR | P06401 | 3/20 | 0.83 |
| ▸ | AR | P10275 | 3/20 | 0.83 |
| ▸ | TSHR | P16473 | 2/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.83 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.83 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol SCHEMBL348107 | 1.00 | LMNA (0.83) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL28378622 | 0.99 | LMNA (0.81) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL1903738 | 0.94 | LMNA (0.83) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL301392 | 0.92 | ESR1 (0.89) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL8092599 | 0.92 | ESR1 (0.89) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL3223253 | 0.92 | ESR1 (0.89) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL7186616 | 0.92 | ESR1 (0.77) | LMNAESR1MAPTHSD17B10KMT2A | |
| Alfatradiol SCHEMBL22092636 | 0.92 | ESR1 (0.77) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL7638916 | 0.92 | ESR1 (0.77) | LMNAESR1MAPTHSD17B10KMT2A | |
| Estradiol SCHEMBL40565 | 0.92 | ESR1 (0.77) | LMNAESR1MAPTHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180171288-A1 | METHODS OF TREATING CANCER | UNIVERSITY OF ROCHESTER | 2018-06-21 | — | — | US | claimed |
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110097405-A1 | ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | US | claimed |
| US-7846916-B2 | Enhanced drug delivery in transdermal systems | Noven Pharamaceticals, Inc. (US) | 2010-12-07 | — | — | US | claimed |
| EP-2249803-A2 | ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-11-17 | — | — | EP | claimed |
| WO-2009101021-A2 | ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-08-20 | — | — | WO | claimed |
| EP-1814526-A2 | ORAL SOLID DOSAGE FORMS CONTAINING A LOW DOSE OF ESTRADIOL | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-08 | — | — | EP | claimed |
| US-20060111334-A1 | Oral solid dosage forms containing a low dose of estradiol | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-25 | — | — | US | claimed |
| WO-2006048261-A2 | ORAL SOLID DOSAGE FORMS CONTAINING A LOW DOSE OF ESTRADIOL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | claimed |
| US-20040043943-A1 | Method for the management of incontinence | ALZA CORPORATION | 2004-03-04 | — | — | US | claimed |
| US-5200197-A | Contraceptive pill | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | claimed |
| EP-0256668-B1 | METHOD FOR TREATING MALE SEXUAL DYSFUNCTION | UNIVERSITY OF FLORIDA (US) | 1992-11-04 | — | — | EP | claimed |
| EP-0500793-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL. | ALZA CORP (US) | 1992-09-02 | — | — | EP | claimed |
| US-5098714-A | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1992-03-24 | — | — | US | claimed |
| WO-1991007173-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| US-4948593-A | SUSTAINED AND CONTROLLED CONTRACEPTION | ALZA CORPORATION (US) | 1990-08-14 | — | — | US | claimed |
| US-4863911-A | Method for treating male sexual dysfunction | UNIVERSITY OF FLORIDA (US) | 1989-09-05 | — | — | US | claimed |
| EP-0256668-A2 | Method for treating male sexual dysfunction | UNIVERSITY OF FLORIDA (US) | 1988-02-24 | — | — | EP | claimed |
| EP-0220844-A2 | Use of estrogen-dihydropyridine compounds for weight control | UNIVERSITY OF FLORIDA (US) | 1987-05-06 | — | — | EP | claimed |
| US-4617298-A | STEROIDS | UNIVERSITY OF FLORIDA (US) | 1986-10-14 | — | — | US | claimed |